Amy Baird
Nurse Practitioner · Louisville, KYNPI 1073697546
Payments from drug & device makers
Across 412 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$912
- Abbott$888
- Insulet Corporation$588
- Boehringer Ingelheim$335
- Esperion Therapeutics, Inc.$313
- plus $3K from 35 others
What the payments were for
- Food & beverage$7,081100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $1,026 |
| Lilly USA, LLC | 48 | $912 |
| Abbott | 55 | $888 |
| Insulet Corporation | 29 | $588 |
| Boehringer Ingelheim | 22 | $335 |
| Esperion Therapeutics, Inc. | 21 | $313 |
| AstraZeneca(2 entities) | 16 | $301 |
| Tandem Diabetes Care, Inc. | 10 | $290 |
| Sanofi-aventis U.S. LLC | 13 | $217 |
| Amgen | 12 | $212 |
| Recordati_rare_diseases_inc. | 11 | $193 |
| Xeris Pharmaceuticals, Inc. | 9 | $187 |
| Medtronic | 10 | $162 |
| Mannkind Corporation | 10 | $152 |
| Corcept Therapeutics | 8 | $148 |
| AbbVie | 8 | $136 |
| Bayer | 8 | $123 |
| Sequel Med Tech, LLC | 3 | $89 |
| Amarin Pharma, Inc. | 5 | $86 |
| Antares Pharma, Inc. | 5 | $81 |
| Ultragenyx Pharmaceutical Inc. | 4 | $69 |
| Dexcom, Inc. | 4 | $57 |
| Cequr Corporation | 2 | $53 |
| Novartis | 2 | $46 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| Zealand Pharma US, Inc. | 3 | $41 |
| Chiesi USA, Inc. | 2 | $40 |
| EUSA Pharma (US) LLC | 2 | $34 |
| Merck | 2 | $34 |
| RGH Enterprises LLC | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| BETA Bionics, Inc. | 2 | $27 |
| Pfizer | 1 | $25 |
| BD | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| GRT US Holding, Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
How this compares
$7,108 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 247 | $362,699 |
| TrulicityDulaglutide | 69 | $109,961 |
| JardianceEmpagliflozin | 97 | $107,978 |
| MounjaroTirzepatide | 68 | $104,523 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $84,371 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $79,138 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $51,888 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $44,782 |
| RybelsusSemaglutide | 14 | $34,692 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $27,128 |
| Humalog Kwikpen U-100Insulin Lispro | 65 | $26,949 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 131 | $24,199 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $23,995 |
| JanuviaSitagliptin Phosphate | 21 | $22,872 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $22,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,026 | $428,772311 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $912 | $227,315177 claims |
| Boehringer IngelheimJardiance | $335 | $107,97897 claims |
| MerckJanuvia, Janumet Xr | $34 | $37,62841 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $217 | $24,61938 claims |
| Esperion Therapeutics, Inc.Nexletol | $313 | $8,29411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $1,817185 claims |
| AbbVieSynthroid | $136 | $1,44523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Louisville
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Rebecca BraunerLouisville$40K
- Thomas FreelsLouisville$20K
- Christy BakerLouisville$18K
- Blair WagnerLouisville$15K
- Kathryn WestLouisville$13K
- Kimberly RobinsonLouisville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.